Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT00271180

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products — Recruiting • Cardiology / Cardiovascular • NCT00271180.

📅 07 May 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT00271180
Start
1983-01
Completion
2040-12
ClinicaliQ Trial Snapshot
  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products — Recruiting • Cardiology / Cardiovascular • NCT00271180.
  • Medtronic reviewed how long cardiac devices last and how often they fail in routine clinical practice.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia Interventions: Device Lead Sponsor: Medtronic Planned Enrollment: 20000 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure
Cardiology / Cardiovascular · 30 Mar 2026
This EMA guideline addresses EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure in Cardiology / Cardiovascular. Use it to…
View guideline →
Guideline
2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy
Cardiology / Cardiovascular · 30 Mar 2026
Covers indications for cardiac pacing and cardiac resynchronization therapy (CRT) • Provides guidance on device selection, implantation techniques, and optimization • Addresses…
View guideline →
Guideline
Heart Failure: Diagnosis and Management (NICE NG106)
Cardiology / Cardiovascular · 27 Mar 2026
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible…
View guideline →
Guideline
Aortic Valve Disease: TAVI and Surgical Replacement (NICE TA631)
Cardiology / Cardiovascular · 27 Mar 2026
Offer TAVI as first-line intervention for symptomatic aortic stenosis in patients at high or prohibitive surgical risk, or with severe comorbidities precluding…
View guideline →
Clinical Brief
People searching NHS advice on high blood pressure skyrocketed last year
Cardiology / Cardiovascular · NHS England · 21 Feb 2026
The number of people searching for trusted NHS advice on high blood pressure surged in 2025 with hundreds of thousands of extra…
View brief →
Clinical Brief
Mesalazine and idiopathic intracranial hypertension
Cardiology / Cardiovascular · MHRA · 04 Dec 2025
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are…
View brief →